Actual Sciences Co. (NASDAQ:EXAS – Get Rating) noticed unusually massive choices buying and selling on Tuesday. Merchants acquired 6,480 put choices on the corporate. This represents a rise of roughly 69% in comparison with the common every day quantity of three,828 put choices.
Analyst Rankings Adjustments
A number of brokerages have just lately commented on EXAS. Citigroup reduce their goal value on Actual Sciences from $50.00 to $35.00 in a analysis report on Friday, November 4th. Craig Hallum upped their goal value on Actual Sciences from $35.00 to $44.00 in a analysis report on Monday. Raymond James reduce their goal value on Actual Sciences from $70.00 to $60.00 and set an “outperform” score on the inventory in a analysis report on Monday, November seventh. SVB Leerink elevated their value goal on Actual Sciences from $60.00 to $70.00 and gave the inventory an “outperform” score in a analysis report on Friday. Lastly, Robert W. Baird reduce their value goal on Actual Sciences from $75.00 to $60.00 in a analysis report on Friday, November 4th. 5 equities analysis analysts have rated the inventory with a maintain score and eight have issued a purchase score to the corporate. In response to MarketBeat, the inventory at the moment has a median score of “Reasonable Purchase” and a median goal value of $61.21.
Actual Sciences Value Efficiency
Exact Sciences stock traded up $1.56 throughout noon buying and selling on Tuesday, reaching $60.38. The corporate had a buying and selling quantity of 27,114 shares, in comparison with its common quantity of two,567,530. Actual Sciences has a 12-month low of $29.27 and a 12-month excessive of $84.46. The agency’s fifty day easy shifting common is $45.32 and its 200-day easy shifting common is $41.51. The corporate has a present ratio of two.47, a fast ratio of two.20 and a debt-to-equity ratio of 0.72.
Actual Sciences (NASDAQ:EXAS – Get Rating) final launched its quarterly earnings knowledge on Thursday, November third. The medical analysis firm reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.26. Actual Sciences had a unfavorable return on fairness of twenty-two.10% and a unfavorable internet margin of 35.73%. The corporate had income of $523.07 million for the quarter, in comparison with analyst estimates of $500.78 million. On common, analysts anticipate that Actual Sciences will publish -3.84 EPS for the present yr.
Insiders Place Their Bets
In different information, insider Everett Cunningham offered 16,872 shares of the inventory in a transaction on Wednesday, October twelfth. The inventory was offered at a median value of $31.37, for a complete transaction of $529,274.64. Following the completion of the sale, the insider now owns 18,654 shares within the firm, valued at roughly $585,175.98. The sale was disclosed in a doc filed with the SEC, which is accessible by way of the SEC website. 1.30% of the inventory is owned by firm insiders.
Institutional Traders Weigh In On Actual Sciences
A number of hedge funds and different institutional buyers have just lately added to or decreased their stakes in EXAS. Armistice Capital LLC bought a brand new stake in shares of Actual Sciences within the third quarter valued at roughly $50,684,000. Capital World Traders lifted its stake in Actual Sciences by 17.2% in the course of the first quarter. Capital World Traders now owns 5,487,009 shares of the medical analysis firm’s inventory value $383,652,000 after buying an extra 804,159 shares within the final quarter. Sumitomo Mitsui Belief Holdings Inc. boosted its place in shares of Actual Sciences by 12.2% in the course of the third quarter. Sumitomo Mitsui Belief Holdings Inc. now owns 6,517,145 shares of the medical analysis firm’s inventory value $211,742,000 after shopping for an extra 709,540 shares in the course of the interval. Vanguard Group Inc. grew its stake in shares of Actual Sciences by 4.4% within the third quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical analysis firm’s inventory valued at $541,823,000 after shopping for an extra 698,740 shares within the final quarter. Lastly, ARK Funding Administration LLC raised its holdings in shares of Actual Sciences by 4.5% within the 2nd quarter. ARK Funding Administration LLC now owns 14,971,765 shares of the medical analysis firm’s inventory valued at $745,744,000 after shopping for an extra 647,803 shares in the course of the interval. Institutional buyers and hedge funds personal 90.30% of the corporate’s inventory.
About Actual Sciences
Actual Sciences Company gives most cancers screening and diagnostic take a look at merchandise in the USA and internationally. The corporate provides Cologuard, a non-invasive stool-based DNA screening take a look at to detect DNA and hemoglobin biomarkers related to colorectal most cancers and pre-cancer. It additionally gives Oncotype DX, a gene expression assessments for breast, prostate, and colon cancers; Oncotype Take a look at, a tissue take a look at delivering tumor profiling to assist remedy choice for sufferers with superior, metastatic, refractory, or recurrent most cancers; Oncotype DX AR-V7 Nucleus Detect Take a look at, a liquid-based take a look at for superior stage prostate most cancers; Oncomap ExTra, that gives an entire organic image of sure refractory, uncommon, or aggressive cancers; and Covid-19 testing companies.
This prompt information alert was generated by narrative science expertise and monetary knowledge from MarketBeat in an effort to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you take into account Actual Sciences, you may wish to hear this.
MarketBeat retains observe of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Actual Sciences wasn’t on the listing.
Whereas Actual Sciences at the moment has a “Reasonable Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.